title: Cardiovascular toxicities of cancer chemotherapy.
abstract: Cancer chemotherapy has improved over the years with the advent of newer agents, including more targeted chemotherapeutic drugs, resulting in better patient survival. However, with continued use and patient exposure to these drugs, important cardiovascular adverse effects are becoming realized, such as left ventricular dysfunction and heart failure, myocardial ischemia, hypertension, arrhythmias, and pulmonary arterial hypertension. In this article, we review the most common cardiovascular toxicities and their related pathophysiology that occur with the use of these agents.
authors.affiliation: Department of Medicine, Division of Cardiology, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA. raphael.bonita@jefferson.edu
authors.forename: Raphael
authors.initials: R
authors.lastname: Bonita
authors.forename: Rajesh
authors.initials: R
authors.lastname: Pradhan
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D006333:Heart Failure / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy*; D013318:Stroke Volume / Q000187:drug effects; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D015415:Biomarkers